Evidence map›Paper›PMID 33274255›Full record

ArticleInternational journal of particle therapy2020

Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States.

Timothy D Malouff, Laura A Vallow, Danushka Seneviratne, Anita Mahajan, Robert L Foote, Bradford Hoppe, Chris Beltran, Steven J Buskirk, Sunil Krishnan, Daniel M Trifiletti

Open access · diamondAbstract read
In one paragraph

Article in International journal of particle therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Timothy D MalouffDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Laura A VallowDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Danushka SeneviratneDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Anita MahajanDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Robert L FooteDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Bradford HoppeDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Chris BeltranDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Steven J BuskirkDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Sunil KrishnanDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Daniel M TrifilettiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Mayo Clinic in Florida · USMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCarbon ion radiotherapy (CIRT) is an emerging radiotherapy modality with potential advantages over conventional photon-based therapy, including exhibiting a Bragg peak and greater relative biological effectiveness, leading to a higher degree of cell kill. Currently, 13 centers are treating with CIRT, although there are no centers in the United States. We aimed to estimate the number of patients eligible for a CIRT center in the United States. MATERIALS AND

methodsUsing the National Cancer Database, we analyzed the incidence of cancers frequently treated with CIRT internationally (glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, locally advanced pancreatic cancer, non-small cell lung cancer, localized prostate cancer, soft tissue sarcomas, and specific head and neck cancers) diagnosed in the United States in 2015. The percentage and number of patients likely benefiting from CIRT was estimated with inclusion criteria from clinical trials and retrospective studies, and that ratio was applied to 2019 cancer statistics. An adaption correction rate was applied to estimate the potential number of patients treated with CIRT. Given the high dependency on prostate and lung cancers and the uncertain adoption of CIRT in those diseases, the data were then reanalyzed excluding those diagnoses.

resultsOf the 1 127 455 new cases of cancer diagnosed in the United States in 2015, there were 213 073 patients (18.9%) eligible for treatment with CIRT based on inclusion criteria. When applying this rate and the adaption correction rate to the 2019 incidence data, an estimated 89 946 patients (42.2% of those fitting inclusion criteria) are eligible for CIRT. Excluding prostate and lung cancers, there were an estimated 8922 patients (10% of those eligible for CIRT) eligible for CIRT. The number of patients eligible for CIRT is estimated to increase by 25% to 27.7% by 2025.

conclusionOur analysis suggests a need for CIRT in the United States in 2019, with the number of patients possibly eligible to receive CIRT expected to increase during the coming 5 to 10 years.

Indexed as

carbonhadronheavyUS

Identifiers

PMID33274255
PMCPMC7707324
OpenAlexW3097826308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.